Weight Loss Interventions in Obese Patients With Stages 3-4 Chronic Kidney Disease: a Randomised Controlled Trial

Recruiting

You are on the General Public view
  • Source

    -
    Public Title Weight Loss Interventions in Obese Patients With Stages 3-4 Chronic Kidney Disease: a Randomised Controlled Trial
    Acronym Sorry, not currently available
    Source of Record URL http://clinicaltrials.gov/show/NCT01053130
  • Trial

    -
    Health Condition(s) or Problem Chronic Kidney Disease; Obesity
    Lay Summary Weight loss surgery is the most effective weight loss treatment available, but the direct effect on chronic kidney disease is less widely understood. Early research shows some improvement in kidney function may occur and candidacy for kidney transplantation can be improved with weight loss following surgery. To date, no randomised controlled trial has been performed to examine the effect of weight loss surgery on the progression of chronic kidney disease. This randomised trial will allocate patients to either lifestyle modification with diet, exercise and pharmacotherapy, or weight loss surgery to remove two thirds of the stomach using the laparoscopic sleeve gastrectomy procedure. This study aims to evaluate weight loss surgery vs lifestyle modification in patients with chronic kidney disease with estimated kidney function of 20-60% and morbid obesity (BMI 35-45) in terms of kidney function, cardiovascular disease risk factors and all-cause mortality. (from ClinicalTrials.gov)
    Who can enter the trial Inclusion Criteria: - Stages 3-4 CKD patients (GFR 20-60 mL/min) - Male or female - BMI 35-45 kg/m2 - Aged >18 years - Previously attempted weight loss - Fit or anesthesia and surgery - Written informed consent Exclusion Criteria: - Pregnancy - History of chronic liver disease - Previous gastric surgery or large hiatus hernia - Previous bariatric surgery - Psychiatric illness, including anxiety, mood and untreated eating disorders - Malnutrition (assessed by subjective global assessment) - Infection or course of antibiotics within the last month - Unwilling to consider surgical treatment - Previous kidney transplant
    Who cannot enter the trial Inclusion Criteria: - Stages 3-4 CKD patients (GFR 20-60 mL/min) - Male or female - BMI 35-45 kg/m2 - Aged >18 years - Previously attempted weight loss - Fit or anesthesia and surgery - Written informed consent Exclusion Criteria: - Pregnancy - History of chronic liver disease - Previous gastric surgery or large hiatus hernia - Previous bariatric surgery - Psychiatric illness, including anxiety, mood and untreated eating disorders - Malnutrition (assessed by subjective global assessment) - Infection or course of antibiotics within the last month - Unwilling to consider surgical treatment - Previous kidney transplant
    What will happen Procedure; laparoscopic sleeve gastrectomy; laparoscopic sleeve gastrectomy plus dietary and physical activity support; weight loss surgery; Behavioral; weight management program; 1200-1500 kcal renal diet, increased physical activity, with optional orlistat therapy at 120 mg tds for 12 months; Lifestyle Intervention
    Primary aim Measured glomerular filtration rate (renal function) using the iohexol clearance method in patients with stages 3-4 chronic kidney disease
    Secondary Aim Composite end point of death and cardiovascular outcomes (stroke, myocardial infarction or congestive heart failure hospitalisation); 0, 6, 12, 24, 36 months; No; Quality of life and anxiety and depression assessment; 0, 6, 12, 24, 36 months; No; Urinary albumin to creatinine ratio and protein to creatinine ratio; 0, 6, 12, 24, 36 months; No; Body composition (weight, BMI, waist and hip circ, BIA); 0, 6, 12 months; No; Insulin resistance (HOMA method); 0, 6, 12 months; No; Serum adiponectin, leptin, IL-6, TNF-a, hs-CRP, fetuin a; 0, 6, 12 months; No; Urinary markers IL-6, MCP-1, IL-1ß, RBP, NAG; 0, 6, 12 months; No; Endothelial function (flow mediated dilatation); 0, 6, 12 months; No
    Participant Information Sheet Sorry, not currently available
    Website Sorry, not currently available
    Recruitment Status Recruiting
    Nation England
    Location London
  • Contact

    -
    Contact for Public Queries Helen L MacLaughlin, BSc (Hons) + 44 20 7848 0431 helen.maclaughlin@kch.nhs.uk
    Contact for Scientific Queries Helen L MacLaughlin, BSc (Hons); Principal Investigator
Please note:
  1. The UKCTG information is designed to inform you of existing trials. If you wish to join a specific trial, you must discuss this with your own doctor who may decide to get in touch with the contact listed.
  2. The UKCTG is not responsible for the quality of the data displayed in the Gateway but can contact the data providers. Please contact us if you have any query regarding the quality of trial records.